Research ArticleATOPIC DERMATITIS

Therapeutic responses to Roseomonas mucosa in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair

See allHide authors and affiliations

Science Translational Medicine  09 Sep 2020:
Vol. 12, Issue 560, eaaz8631
DOI: 10.1126/scitranslmed.aaz8631

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A rosy outlook for Roseomonas

In a clinical trial, topical application of the healthy skin bacterium Roseomonas mucosa improved atopic dermatitis (AD) in children age 3 years or older. R. mucosa treatment was associated with improvements in disease symptoms, epithelial barrier function, the amount of Staphylococcus aureus growing on the skin, the need for topical steroids, and quality of life for children and their families. Clinical improvements and colonization of skin by R. mucosa persisted for up to 8 months after treatment cessation and were not associated with major adverse events. Cell culture analyses and studies in the MC903 mouse model of AD suggest that the therapeutic mechanism may involve lipid production by R. mucosa, cholinergic signaling, and flagellin expression leading to a TNFR2-mediated epithelial-to-mesenchymal transition.

View Full Text

Stay Connected to Science Translational Medicine